An interventional study of Standard, high-definition colonoscopy with the use of CADe assistance and Standard, high-definition colonoscopy with the use of CADe/CADx assistance, no leave-in-situ in Colonic Neoplasms, sponsored by Istituto Clinico Humanitas. Recruiting at 2 sites in Italy. Open to participants aged 40 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-30.
Sponsored by Istituto Clinico Humanitas · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 135 studies in Colonic Neoplasms with a site in Italy — 41 open to participants now, 56 under way, 8 of them phase 3. Colonic Neoplasms · Italy.
Among the 135 studies in Colonic Neoplasms with a site in Italy, this one is the 6th largest by planned enrollment of the 87 interventional ones that give a count, is one of 13 that started in 2023, is one of 29 with no phase, reaches primary completion later than 33 of the 55 other live ones, and was the 100th registered.
2,457 studies on the registry are indexed under Colonic Neoplasms; 456 are open to participants now.
Browse Colonic Neoplasms studies →41 of the 135 studies in Colonic Neoplasms with a site in Italy are open now. Recruiting first, the newest first:
Solstice Oncology, Inc. · Sites in Italy, United States, Belgium and 3 more countries
Ages 18+
Matteo Clavarezza · Sites in Italy
Ages 70–99
Incyte Corporation · Sites in Italy, United States, Argentina and 19 more countries
Ages 18+
Pfizer · Sites in Italy, United States, Argentina and 17 more countries
Ages 18+
Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis · Sites in Italy
Ages 18+ · Healthy volunteers
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 326 Colonic Neoplasms studies recruiting now, 202 (62%) set no upper age limit and 72 (22%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.
This study: 40 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
135 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 29 · Phase 3 27
First in 1991; this study’s year is marked. 13 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,800 is above the median of 75 across 1,711 interventional studies indexed under Colonic Neoplasms.
Median enrollment 222 across the 87 interventional studies, 345 across the 44 observational. Of the 58 that completed or were terminated, 9 (16%) have results posted.
This tab as a report to print or save as PDF → With an account.
36 of 135 have an industry lead sponsor. The 10 most frequent:
Istituto Clinico Humanitas is the lead sponsor of 280 studies on the registry; 70 are open to participants now.
Istituto Clinico Humanitas has 5 studies filed under Colonic Neoplasms — fewer than ten, so there is no comparison to draw.
13 of the studies in Colonic Neoplasms with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06567782GlaxoSmithKlineA Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III Mismatch Repair Proficient (MMRp)/Microsatellite Stable (MSS) Colon Cancer | 2026-11-23 |
| NCT07153458Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de BellisIdentification of New Non-invasive, Predictive, and Diagnostic Biomarkers for Colorectal Cancer | 2026-12-01 |
| NCT05714124IRCCS San RaffaeleLiver Embolization Approaches for Tumor Management | 2026-12-31 |
| NCT05186116Azienda Ospedaliero-Universitaria di ModenaLDLT in Non Resectable Colo-rectal Cancer Liver Metastasis | 2027-01-01 |
| NCT04871399University of Turin, ItalyComplete Mesocolic Excision in Comparison With Conventional Surgery for the Right Colon Cancer | 2027-01-01 |
Add all 13 to your calendar (.ics) → With an account.
Among the 135 studies in Colonic Neoplasms with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This three parallel-arms, randomized, multicenter trial is aimed at investigating the value of AI-assisted optical biopsy for differentiating between neoplastic and non-neoplastic polyps which will lead to the implementation of cost-saving strategies in screening programs. A cost-effectiveness analyses with the use of modern trial emulation analyses of large observational and clinical trial datasets and real-cost data will be conducted. To improve personalized treatment with a novel colonoscopy CADx risk-prediction tool, the investigators will even develop a novel deep learning algorithm for the optical biopsy of the alternative pathway of colorectal cancer carcinogenesis, namely the serrated pathway and develop cost-effectiveness models of AI-assisted optical biopsy in colorectal cancer screening that provides reliable information to identify cancer risk regardless of physicians' skill.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Standard, high-definition colonoscopy with the use of CADe assistance (GI-GENIUS, Medtronic; CAD-EYE, Fujifilm; WISE VISION ,NEC). All detected polyps regardless of size and optical diagnosis will be resected and sent to pathology.
Device: Standard, high-definition colonoscopy with the use of CADe assistance
Standard, high-definition colonoscopy with the use of CADe/CADx assistance (GI-GENIUS, Medtronic; CAD-EYE, Fujifilm; WISE VISION ,NEC). All detected polyps regardless of size and optical diagnosis will be resected and sent to pathology.
Device: Standard, high-definition colonoscopy with the use of CADe/CADx assistance, no leave-in-situ
Standard, high-definition colonoscopy with the use of CADe/CADx assistance (GI-GENIUS, Medtronic; CAD-EYE, Fujifilm; WISE VISION, NEC). Polyps will be left in situ if diminutive (≤5 mm) in size, located in the rectum or sigma and optically diagnosed by the endoscopist using the system to be hyperplastic with high confidence, otherwise resected and sent to pathology.
Device: Standard, high-definition colonoscopy with the use of CADe/CADx assistance, leave-in-situ
All detected polyps regardless of size and optical diagnosis will be resected and sent to pathology.
All detected polyps regardless of size and optical diagnosis will be resected and sent to pathology.
Polyps will be left in situ if diminutive (≤5 mm) in size, located in the rectum or sigma and optically diagnosed by the endoscopist using the system to be hyperplastic with high confidence, otherwise resected and sent to pathology.
Non-inferiority in Adenoma Detection Rate
Non-inferiority in the Adenoma Detection Rate, defined as the proportion of participants with at least one adenoma (per-patient analysis) in the three arms, when adopting a cost-saving leave-in-situ strategy for non-neoplastic rectosigmoid diminutive polyps.
Time frame: 4 years
Negative Predictive Value for colorectal neoplasia
Negative Predictive Value for colorectal neoplasia when adopting a leave-in-situ strategy for rectosigmoid diminutive polyps based on the use of Artificial Intelligence.
Time frame: 4 years
Concordance between post-polypectomy surveillance and when adopting a leave-in-situ strategy
Concordance between post-polypectomy surveillance based on strategies based on optical diagnosis with Artificial Intelligence and those based on histology, and when adopting a leave-in-situ strategy for colorectal diminutive polyps based on the use of Artificial Intelligence
Time frame: 4 years
Change in the cost of polypectomy and histology in screening programs
Change in the cost of polypectomy and histology in screening programs, when implementing strategies based on Artificial Intelligence-based optical biopsy, without changes in benefit related with detection of colorectal neoplasia
Time frame: 4 years
Started Sep 2023 (actual). Primary completion is estimated for Sep 2027, 47 months after the start.
Of 382 non-industry interventional studies with no phase under Colonic Neoplasms, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 55. This study's planned 47 months is above that.
Counting every sponsor, half of 404 studies reached it within 30 months; a quarter within 16 and three quarters within 51.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.